Acquisitions, Investments, and Licenses - Summary of Pro Forma Results (Details) - Transition Therapeutics, Inc. - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues	$ 1,221,661	$ 491,738
Net loss	(31,807)	(50,660)
Net loss attributable to common shareholders	$ (31,807)	$ (49,260)